Stay updated on Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial
Sign up to get notified when there's something new on the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page.

Latest updates to the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page
- Check5 days agoChange DetectedA new revision entry, v3.4.3, was added to the record history and the previous revision, v3.4.2, was removed. This is an administrative update to the page's version history.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedThe record history shows the addition of revision v3.4.2 and removal of v3.4.1. This is a metadata update to the page with no changes to study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedThe record history now includes a new revision entry v3.4.1 and removes v3.4.0, reflecting a system site update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedGlossary toggle and color-coded change highlights (green for additions, red for deletions) were added, along with a new Revision: v3.4.0 label; the No FEAR Act data text and the Revision: v3.3.4 entry were removed.SummaryDifference1%

- Check62 days agoChange DetectedNew revision v3.3.4 added to the Record History; the previous revision v3.3.3 is shown in the history.SummaryDifference0.1%

- Check84 days agoChange DetectedDifference0.2%

Stay in the know with updates to Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page.